CEO COMMENTS

Kristina Torfgård comments Q2 report 2025

“I have now been CEO of IRLAB for just over a year – a period marked by intensive work, progress, collaborations, and important decisions, which we are now building on with full force. The positive development we saw at the beginning of the year has continued during the second quarter, and I am particularly pleased with the progress we have made in our three most advanced projects. Our portfolio of drug candidates is strong, with several now ready for or approaching out-licensing and partnerships. Thanks to the capital raised from the rights issue carried out this past summer, we can now continue to drive the prioritized activities aimed at establishing partnerships and licensing agreements for our candidates and thereby realizing the commercial value of the projects.

Key Milestones During the Quarter and after:

• The application to start a Phase Ib study with IRL757 in patients with Parkinson’s and apathy is ready to submit. Our strategic partnerships with MSRD/Otsuka and the Michael J. Fox Foundation are key drivers in the development of IRL757.
• The recently granted patent for mesdopetam in the US further strengthens the already robust patent and exclusivity protection with the potential for market exclusivity well into the 2040s.
• New study data for pirepemat confirm the potential for continued development, and an additional study is planned to optimize dosing.

Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”

Q3’24

Interim report >

Presentation >

Webcast >

Q4’24

Year-end report >

Presentation >

Webcast >

Q1’25

Interim report >

Presentation >

Webcast >

Q2’25

Interim report >

Presentation >

Webcast >

FINANCIAL CALENDAR

NEXT

October 29 2025

Interim Report January – September 2025